Here we demonstrate that a CXCR2 antagonist, AZD5069, as a single agent, was beneficial in the prevention of progression of insulin resistance and liver pathology reminiscent of NASH/NAFLD. This evidence concerns the gene CXCR2 and metabolic dysfunction-associated steatohepatitis.